Aktis Oncology (AKTS) investor relations material

Strategic vision, positioning, and platform development

• Positioned as a leader in next-generation targeted radiopharmaceuticals, leveraging a proprietary mini-protein radioconjugate platform and a strong balance sheet.

• Aims to expand radiopharmaceuticals to new patient subsets lacking current options, utilizing a screening library of over 6 billion variants and generative AI to accelerate discovery.

• Collaboration with Eli Lilly has achieved its first milestone, enhancing discovery capabilities and pipeline development, with further candidates expected to be named early next year.

• Well-capitalized with $538 million in cash, providing runway into 2029.

Clinical pipeline, progress, and data highlights

• Two lead assets, AKY-1189 (Nectin-4) and AKY-2519 (B7-H3), are in clinical trials targeting large market tumor types with first-in-class potential, supported by imaging proof-of-concept.

• AKY-1189 targets Nectin-4 expressing solid tumors, has Fast Track designation for metastatic urothelial cancer, and demonstrates robust tumor uptake and favorable clearance from normal tissues.

• AKY-2519 targets B7-H3 expressing tumors, including mCRPC, lung, and colorectal cancers, with IND clearance and Phase 1b trials initiated in 2Q 2026; shows high tumor retention and low normal tissue exposure.

• Ongoing and planned trials include NECTINIUM-2 Phase 1b for AKY-1189, BActinium-1 in prostate cancer, and a BActinium-2 basket study for other solid tumors starting in the second half of the year.

• Both programs target multi-indication, multi-disease opportunities, aiming for mega-blockbuster potential and addressing up to 193K and 215K patients, respectively.

Market opportunity and competitive landscape

• Lead programs address large patient populations, with forecasted peak sales for comparables (PLUVICTO, PADCEV) ranging from $5.4B to $7.0B.

• Pricing benchmarks for similar therapies are $300K–$500K per year.